NeuroPatch Devices Reports 94% Efficacy in Phase III Trial for Bioelectronic Epilepsy Treatment

NeuroPatch Devices Reports 94% Efficacy in Phase III Trial for Bioelectronic Epilepsy Treatment

NeuroPatch Devices, a medical device company headquartered in Minneapolis with R&D facilities in Singapore and Helsinki, has published full results from its landmark NPe-1 (NeuroPatch epicardial) clinical trial in The Lancet Neurology, reporting a 94% seizure reduction efficacy in patients with drug-resistant focal epilepsy — a result that could redefine the standard of care for the 15 million people worldwide who do not respond to anti-epileptic drugs.

The NPe-1 Device

The NPe-1 is a closed-loop vagus nerve stimulation (VNS) system implanted in a 90-minute surgical procedure. Unlike traditional VNS devices that deliver periodic stimulation regardless of brain state, the NPe-1 incorporates a 预测引擎 (prediction engine) — a tiny on-device neural processing unit running a transformer model trained on 40,000 hours of intracranial EEG recordings.

The system continuously monitors cortical activity via leads placed on the brain's surface. When the algorithm detects a pre-seizure electrophysiological signature — a pattern it identifies with 97.2% sensitivity and 0.3% false-positive rate per 24 hours — it delivers a 15-second adaptive electrical pulse train to the left vagus nerve. This autonomic stimulation interrupts the seizure propagation cascade before the patient experiences any symptoms.

Trial Design and Results

The randomized, sham-controlled Phase III trial enrolled 1,200 patients across 23 centers in the US, EU, UK, Japan, and Australia. Patients were implanted and then randomized 1:1 to active NPe-1 or sham (device implanted but stimulation disabled) for a 6-month blinded phase, followed by an open-label extension.

Primary endpoint results at 12 months (active arm, n=596):

• Median seizure frequency reduction: 94% from baseline
• Seizure-free for ≥90 consecutive days: 41% of patients
• Serious adverse events: 2.1% (device infection requiring explant in all cases)
• Device-related serious events: 0.5%

Quality of life metrics (QOLIE-31P score) improved by a mean of 22.3 points versus 4.1 points in the sham arm (p<0.0001).

Regulatory Status

NeuroPatch submitted the NPe-1 for FDA Premarket Approval (PMA) in August 2027 following an interim analysis that triggered early stopping for overwhelming efficacy. The FDA has granted the application Breakthrough Device Designation, and a decision is expected by Q2 2028. CE marking under MDR 2017/745 is also in review, with a decision anticipated by Q3 2028.

The company has simultaneously filed for approval in Japan (PMDA) and Australia (TGA).

Economic and Access Considerations

NeuroPatch has announced an outcomes-based pricing model: $42,000 upfront (comparable to existing VNS systems) plus a $6,000 annual subscription for the algorithm update service. For healthcare systems in low- and middle-income countries, the company is piloting a refundable device loan program through the Global Epilepsy Partnership.

Scientific Significance

The NPe-1 represents a milestone in bioelectronic medicine — the use of electrical signals to modulate disease pathways rather than chemical drugs. Its on-device AI prediction model, trained via federated learning across 40,000 patient recordings (without centralizing raw data), demonstrates a scalable path to personalized neuromodulation.

Dr. Amara Osei, trial principal investigator at Massachusetts General Hospital, called the results "the most significant advance in epilepsy treatment since the introduction of levetiracetam in 1999."

NeuroPatch Devices — Company Profile

Founded in 2021 by biomedical engineer Dr. James Whitfield and neuroscientist Dr. Linnea Pettersson, NeuroPatch Devices has raised $520 million across eight funding rounds. Its Series E ($150M, led by SoftBank Vision Fund 2) closed in March 2027. The company employs 840 people globally and is expanding its manufacturing facility in Singapore to produce 50,000 devices annually by 2029.